GlassScriptPhysician profile
Edward John Rybka
NPI 1790920981
$2,646.48
in general payments reported to CMS, 2019-2025
21 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $234 · 2021: $518 · 2022: $684 · 2023: $674 · 2024: $259 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $578.41 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $481.87 | 2021-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $362.97 | 2020-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $263.18 | 2021-2025 | Wegovy |
| Pfizer INC. | $260.89 | 2019-2025 | |
| Amgen INC. | $128.99 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.26 | 2019-2022 | |
| Allergan, INC. | $106.33 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $59.20 | 2021-2024 | Eliquis |
| Astellas Pharma US INC | $37.94 | 2020-2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $36.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.56 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $28.67 | 2023 | |
| Janssen Pharmaceuticals, INC | $26.70 | 2019 | |
| Madrigal Pharmaceuticals | $25.09 | 2025 | Rezdiffra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.78 | 2021 | |
| Abbott Laboratories | $23.61 | 2024 | Proclaim |
| Phathom Pharmaceuticals, INC. | $19.85 | 2024 | Voquezna |
| Lilly USA, LLC | $15.52 | 2021 | |
| Genentech USA, INC. | $14.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Rybka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.